比较 Tarlatamab 和 Durvalumab 与单独使用 Durvalumab 治疗铂类、依托泊苷和 Durvalumab 后一线广泛期小细胞肺癌 (ES-SCLC) 的研究 (DeLLphi-305)
Tarlatamab 联合 Durvalumab 对比单独使用 Durvalumab 的 3 期、开放标签、多中心、随机研究,用于接受铂类、依托泊苷和 Durvalumab 治疗后患有广泛期小细胞肺癌的受试者
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Beijing、中国、100142
- Beijing Cancer Hospital
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100142
- Beijing Cancer Hospital
-
Beijing、Beijing Municipality、中国、100020
- Beijing Chaoyang Hospital, Capital Medical University
-
-
Chongqing Municipality
-
Chongqing、Chongqing Municipality、中国、400037
- Xinqiao Hospital
-
-
Fujian
-
Fuzhou、Fujian、中国、350014
- Fujian Cancer Hospital
-
Quanzhou、Fujian、中国、362002
- The Second Attached Hospital Of Fujian Medical University
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510060
- Sun Yat-sen University Cancer Center
-
-
Guangxi
-
Guilin、Guangxi、中国、541001
- Affiliated Hospital of Guilin Medical University
-
Nanning、Guangxi、中国、530201
- Guangxi Medical University Affiliated Tumor Hospital
-
-
Hebei
-
Cangzhou、Hebei、中国、061011
- Cangzhou Peoples Hospital
-
-
Heilongjiang
-
Jiamusi、Heilongjiang、中国、154007
- Jiamusi Cancer Hospital
-
-
Henan
-
Zhengzhou、Henan、中国、450003
- Henan Cancer Hospital
-
Zhengzhou、Henan、中国、450066
- The First Affiliated Hospital of Zhengzhou University
-
-
Hubei
-
Wuhan、Hubei、中国、430070
- Hubei Cancer Hospital
-
-
Inner Mongolia
-
Hohhot、Inner Mongolia、中国、010010
- The Affiliated Hospital of Inner Mongolia Medical University
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210029
- Nanjing Chest Hospital
-
Xuzhou、Jiangsu、中国、221009
- Xuzhou Central Hospital
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330029
- Jiangxi Cancer hospital
-
-
Jilin
-
Changchun、Jilin、中国、130012
- Jilin Cancer Hospital
-
-
Shandong
-
Jinan、Shandong、中国、250117
- The Affiliated Cancer Hospital of Shandong First Medical University
-
Linyi、Shandong、中国、276000
- Linyi Cancer Hospital
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200433
- Shanghai Pulmonary Hospital
-
Shanghai、Shanghai Municipality、中国、200030
- Shanghai Chest Hospital
-
-
Shanxi
-
Taiyuan、Shanxi、中国、030009
- Shanxi Provincial Cancer Hospital
-
Xi’an、Shanxi、中国、710065
- The First Affiliated Hospital of Xian Jiaotong University
-
-
Sichuan
-
Chengdu、Sichuan、中国、611135
- West China Hospital of Sichuan University
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300121
- Tianjin Peoples Hospital
-
-
Xinjiang
-
Ürümqi、Xinjiang、中国、830054
- Affiliated Cancer Hospital of Xinjiang Medical University
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310003
- the First Affiliated Hospital Zhejiang University School of Medicine
-
Ningbo、Zhejiang、中国、315010
- The First Affiliated Hospital Of Ningbo University
-
Wenzhou、Zhejiang、中国、325015
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
-
Copenhagen、丹麦、2100
- Rigshospitalet
-
Herning、丹麦、7400
- Regionshospitalet Godstrup
-
Odense C、丹麦、5000
- Odense Universitetshospital
-
-
-
-
-
Haifa、以色列、3109601
- Rambam Medical Center
-
Jerusalem、以色列、9103102
- Shaare Zedek Medical Center
-
Kfar Saba、以色列、4428164
- Meir Medical Center
-
Petah Tikva、以色列、4941492
- Rabin Medical Center
-
-
-
-
Ontario
-
London、Ontario、加拿大、N6A 5W9
- London Health Sciences Centre
-
-
Quebec
-
Québec、Quebec、加拿大、G1R 2J6
- CHU de Quebec Hopital de l Enfant Jesus
-
-
-
-
-
Budapest、匈牙利、1083
- Semmelweis Egyetem
-
Budapest、匈牙利、1121
- Orszagos Koranyi Pulmonologiai Intezet
-
Gyöngyös、匈牙利、3200
- Matrai Gyogyintezet
-
Győr、匈牙利、9024
- Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktatokorhaz
-
Székesfehérvár、匈牙利、8000
- Fejer Varmegyei Szent Gyorgy Egyetemi Oktato Korhaz
-
Törökbálint、匈牙利、2045
- Reformatus Pulmonologiai Centrum
-
-
-
-
-
Kaohsiung City、台湾、83301
- Kaohsiung Chang Gung Memorial Hospital
-
Tainan、台湾、70403
- National Cheng Kung University Hospital
-
Taipei、台湾、10002
- National Taiwan University Hospital
-
Taipei、台湾、11217
- Taipei Veterans General Hospital
-
-
-
-
-
Ankara、土耳其(türkiye)、06800
- Ankara Bilkent Sehir Hastanesi
-
Istanbul、土耳其(türkiye)、34214
- Bagcilar Medipol Mega Universite Hastanesi
-
Izmir、土耳其(türkiye)、35150
- Izmir Katip Celebi Universitesi Ataturk Egitim ve Arastirma Hastanesi
-
Mersin、土耳其(türkiye)、33200
- Medical Park Seyhan Hastanesi
-
Mersin、土耳其(türkiye)、33200
- VM Medical Park Mersin Hastanesi
-
Sakarya、土耳其(türkiye)、54290
- Sakarya Egitim ve Arastirma Hastanesi
-
-
-
-
Mexico City
-
Mexico City、Mexico City、墨西哥、03810
- Oncare
-
Mexico City、Mexico City、墨西哥、03100
- Health Pharma Professional Research SA de CV
-
-
-
-
-
Graz、奥地利、8036
- Medizinische Universitaet Graz
-
Krems、奥地利、3500
- Universitaetsklinikum Krems
-
Rankweil、奥地利、6830
- Landeskrankenhaus Feldkirch
-
-
-
-
-
Rio de Janeiro、巴西、22250-905
- Oncoclinicas Rio de Janeiro S A
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、巴西、40170-110
- Hospital Sao Rafael-Idor
-
-
Minas Gerais
-
Belo Horizonte、Minas Gerais、巴西、30130-090
- Cenantron Centro Avançado de Tratamento Oncologico Ltda
-
Passos、Minas Gerais、巴西、37904-020
- Santa Casa de Misericordia de Passos
-
-
Paraná
-
Cascavel、Paraná、巴西、85806-300
- Hospital Uopeccan
-
-
Rio Grande do Sul
-
Ijuí、Rio Grande do Sul、巴西、98700-000
- Hospital de Clinicas de Ijui
-
Passo Fundo、Rio Grande do Sul、巴西、99010-260
- Hospital de Clinicas de Passo Fundo
-
Porto Alegre、Rio Grande do Sul、巴西、90020-090
- Irmandade da Santa Casa de Misericordia de Porto Alegre
-
-
São Paulo
-
São Paulo、São Paulo、巴西、01509-900
- Fundacao Antonio Prudente AC Camargo Cancer Center
-
São Paulo、São Paulo、巴西、05652-900
- Hospital Israelita Albert Einstein
-
-
-
-
-
Athens、希腊、18547
- Metropolitan Hospital
-
Athens、希腊、15562
- Metropolitan General
-
Athens、希腊、12462
- Attikon University Hospital
-
Athens、希腊、11526
- Henry Dunant Hospital Center
-
Athens、希腊、11527
- Sotiria General Hospital
-
Thessaloniki、希腊、55236
- Saint Lukes Hospital SA
-
Thessaloniki、希腊、57001
- European Interbalkan Medical Center
-
-
-
-
-
Cologne、德国、51109
- Kliniken der Stadt Koeln gGmbH
-
Dresden、德国、01307
- Universitaetsklinikum Dresden
-
Essen、德国、45147
- Universitaetsklinikum Essen
-
Gauting、德国、82130
- Asklepios Fachkliniken Muenchen Gauting
-
Großhansdorf、德国、22927
- LungenClinic Grosshansdorf GmbH
-
Heidelberg、德国、69126
- Universitaetsklinikum Heidelberg
-
Münster、德国、48149
- University Hospital Muenster
-
Würzburg、德国、97078
- Universitaetsklinikum Wuerzburg
-
-
-
-
-
Bari、意大利、70124
- IRCCS Istituto Tumori Giovanni Paolo II
-
Milan、意大利、20162
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
-
Milan、意大利、20141
- IRCCS Istituto Oncologico Europeo
-
Verona、意大利、37126
- Centro Ricerche Cliniche Di Verona Societa responsabilita limitata
-
-
-
-
-
Brno、捷克语、625 00
- Fakultni nemocnice Brno
-
Olomouc、捷克语、779 00
- Fakultni nemocnice Olomouc
-
Ostrava-Vitkovice、捷克语、703 00
- Nemocnice Agel Ostrava-Vitkovice as
-
Prague、捷克语、128 08
- Vseobecna fakultni nemocnice v Praze
-
Prague、捷克语、150 06
- Fakultni nemocnice v Motole
-
-
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、464-8681
- Aichi Cancer Center
-
-
Chiba
-
Kashiwa-shi、Chiba、日本、277-8577
- National Cancer Center Hospital East
-
-
Ehime
-
Matsuyama、Ehime、日本、791-0280
- National Hospital Organization Shikoku Cancer Center
-
-
Fukuoka
-
Fukuoka、Fukuoka、日本、812-8582
- Kyushu University Hospital
-
Kurume-shi、Fukuoka、日本、830-0011
- Kurume University Hospital
-
-
Hokkaido
-
Sapporo、Hokkaido、日本、003-0804
- National Hospital Organization Hokkaido Cancer Center
-
-
Hyōgo
-
Akashi-shi、Hyōgo、日本、673-8558
- Hyogo Cancer Center
-
-
Kanagawa
-
Yokohama、Kanagawa、日本、241-8515
- Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center
-
-
Niigata
-
Niigata、Niigata、日本、951-8566
- Niigata Cancer Center Hospital
-
-
Okayama-ken
-
Okayama、Okayama-ken、日本、700-8558
- Okayama University Hospital
-
-
Osaka
-
Hirakata-shi、Osaka、日本、573-1191
- Kansai Medical University Hospital
-
Osaka、Osaka、日本、541-8567
- Osaka International Cancer Institute
-
Osakasayama-shi、Osaka、日本、589-8511
- Kindai University Hospital
-
-
Saitama
-
Hidaka-shi、Saitama、日本、350-1298
- Saitama Medical University International Medical Center
-
-
Shizuoka
-
Sunto-gun、Shizuoka、日本、411-8777
- Shizuoka Cancer Center
-
-
Tokyo
-
Bunkyo-ku、Tokyo、日本、113-8431
- Juntendo University Hospital
-
Chuo-ku、Tokyo、日本、104-0045
- National Cancer Center Hospital
-
Koto-ku、Tokyo、日本、135-8550
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research
-
-
Wakayama
-
Wakayama、Wakayama、日本、641-8510
- Wakayama Medical University Hospital
-
-
-
-
-
Aalst、比利时、9300
- Azorg Campus Aalst - Moorselbaan
-
Brussels、比利时、1090
- Universitair Ziekenhuis Brussel
-
Brussels、比利时、B-1070
- Institut Jules Bordet
-
Brussels、比利时、1200
- Universite Catholique de Louvain Cliniques Universitaires Saint Luc
-
Edegem、比利时、2650
- Universitair Ziekenhuis Antwerpen
-
Genk、比利时、3600
- Ziekenhuis Oost-Limburg
-
Ghent、比利时、9000
- Algemeen Ziekenhuis Maria Middelares
-
Mons、比利时、7000
- Centres Hospitaliers Universitaires - Helora - Hopital de Mons - Site Kennedy
-
Yvoir、比利时、5530
- Centre Hospitalier Universitaire-Universite Catholique de Louvain Namur-Site Godinne
-
-
-
-
-
Bordeaux、法国、33000
- Institut Bergonie
-
Brest、法国、29200
- Centre Hospitalier Regional Universitaire de Brest - Hopital Morvan
-
Créteil、法国、94010
- Centre Hospitalier Intercommunal de Creteil
-
Le Mans、法国、72000
- Centre Hospitalier - Le Mans
-
Lyon、法国、69008
- Centre Leon Berard
-
Marseille、法国、13915
- Centre Hospitalier Universitaire Nord
-
Montpellier、法国、34298
- Institut regional du Cancer Montpellier
-
Paris、法国、75014
- Hopital Cochin
-
Saint-Herblain、法国、44800
- Centre Hospitalier Universitaire de Nantes - Hopital Nord Laennec
-
Strasbourg、法国、67091
- Centre Hospitalier Universitaire de Strasbourg - Nouvel Hopital Civil
-
Toulouse、法国、31059
- Centre Hospitalier Universitaire de Toulouse - Hopital Larrey
-
Valenciennes、法国、59300
- Clinique Teissier
-
-
-
-
-
Gdansk、波兰、80-214
- Uniwersyteckie Centrum Kliniczne
-
Poznan、波兰、60-569
- Wielkopolskie Centrum Pulmonologii i Torakochirurgii imienia Eugenii i Janusza Zeylandow
-
Warsaw、波兰、01-138
- Instytut Gruzlicy i Chorob Pluc
-
Wroclaw、波兰、53-439
- Dolnoslaskie Centrum Onkologii, Pulmonologii i Hematologii
-
-
-
-
New South Wales
-
Camperdown、New South Wales、澳大利亚、2050
- Chris OBrien Lifehouse
-
Wollongong、New South Wales、澳大利亚、2500
- Wollongong Hospital
-
-
Queensland
-
Greenslopes、Queensland、澳大利亚、4120
- Greenslopes Private Hospital
-
-
South Australia
-
Adelaide、South Australia、澳大利亚、5000
- Cancer Research South Australia
-
-
Victoria
-
Clayton、Victoria、澳大利亚、3168
- Monash Medical Centre
-
-
Western Australia
-
Nedlands、Western Australia、澳大利亚、6009
- Sir Charles Gairdner Hospital
-
-
-
-
-
Dublin、爱尔兰、9
- Beaumont Hospital
-
-
-
-
-
Basel、瑞士、4052
- Universitaetsspital Basel
-
Bern、瑞士、3010
- Inselspital Bern
-
Mendrisio、瑞士、6850
- Ospedale Regionale di Bellinzona e Vali
-
Sankt Gallen、瑞士、9007
- Kantonsspital Sankt Gallen
-
-
-
-
-
Cluj-Napoca、罗马尼亚、400015
- Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca
-
Ploieşti、罗马尼亚、100337
- Spitalul Municipal Ploiesti
-
-
-
-
Alabama
-
Mobile、Alabama、美国、36607
- Infirmary Cancer Center
-
-
California
-
Los Angeles、California、美国、90033
- University of Southern California
-
-
Connecticut
-
New Haven、Connecticut、美国、06510
- Yale New Haven Hospital
-
-
Georgia
-
Athens、Georgia、美国、30607
- University Cancer and Blood Center LLC
-
Atlanta、Georgia、美国、30322
- Emory University
-
Gainesville、Georgia、美国、30501
- Northeast Georgia Medical Center
-
-
Illinois
-
Chicago、Illinois、美国、60612
- University of Illinois Chicago
-
-
Indiana
-
Indianapolis、Indiana、美国、46237
- Franciscan Health Indianapolis
-
-
Louisiana
-
Baton Rouge、Louisiana、美国、70808
- Our Lady of the Lake Cancer Institute
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Grand Rapids、Michigan、美国、49503
- Cancer and Hematology Centers of Western Michigan
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- Mayo Clinic
-
Saint Paul、Minnesota、美国、55102
- Allina Health System dba Allina Health Cancer Institute
-
-
Missouri
-
Springfield、Missouri、美国、65807
- Oncology Hematology Associates
-
-
Nebraska
-
Omaha、Nebraska、美国、68130
- Nebraska Cancer Specialists
-
-
New Jersey
-
East Brunswick、New Jersey、美国、08816
- Astera Cancer Care
-
New Brunswick、New Jersey、美国、08901
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
The Bronx、New York、美国、10461
- Montefiore Medical Center - Bronx
-
-
North Carolina
-
Durham、North Carolina、美国、27710
- Duke University
-
Winston-Salem、North Carolina、美国、27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Cincinnati、Ohio、美国、45242
- Oncology Hematology Care Incorporated
-
Cleveland、Ohio、美国、44106
- University Hospitals Cleveland Medical Center
-
Columbus、Ohio、美国、43210
- The Ohio State University
-
-
Oregon
-
Eugene、Oregon、美国、97401
- Oncology Associates of Oregon, PC
-
Portland、Oregon、美国、97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15232
- University of Pittsburgh Medical Center
-
Pittsburgh、Pennsylvania、美国、15212
- Allegheny Health Network
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- Medical University of South Carolina
-
-
Tennessee
-
Memphis、Tennessee、美国、38120
- Baptist Cancer Center Memphis Thoracic
-
Nashville、Tennessee、美国、37203
- Sarah Cannon Research Institute
-
-
Texas
-
Dallas、Texas、美国、75246
- Texas Oncology - Dallas Fort Worth
-
Dallas、Texas、美国、75246
- US Oncology Research Investigational Products Center
-
Houston、Texas、美国、77030
- University of Texas MD Anderson Cancer Center
-
-
Virginia
-
Newport News、Virginia、美国、23606
- Virginia Oncology Associates
-
Richmond、Virginia、美国、23298
- Virginia Commonwealth University Massey Cancer Center
-
-
Washington
-
Seattle、Washington、美国、98104
- Swedish Cancer Institute
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- The Medical College of Wisconsin
-
-
-
-
-
Groningen、荷兰、9713 GZ
- Universitair Medisch Centrum Groningen
-
Maastricht、荷兰、6229 HX
- Maastricht Universitair Medisch Centrum
-
Rotterdam、荷兰、3015 GD
- Erasmus Medisch Centrum
-
-
-
-
-
Lisbon、葡萄牙、1500-650
- Hospital da Luz, SA
-
Lisbon、葡萄牙、1998-018
- Hospital Cuf Descobertas
-
Matosinhos Municipality、葡萄牙、4464-513
- Unidade Local de Saude de Matosinhos, EPE - Hospital Pedro Hispano
-
Porto、葡萄牙、4100-180
- Hospital Cuf porto
-
-
-
-
-
Madrid、西班牙、28034
- Hospital Universitario Ramon y Cajal
-
-
Andalusia
-
Málaga、Andalusia、西班牙、29011
- Hospital Regional Universitario de Malaga
-
Seville、Andalusia、西班牙、41009
- Hospital Universitario Virgen Macarena
-
-
Catalonia
-
Barcelona、Catalonia、西班牙、08036
- Hospital Clinic i Provincial de Barcelona
-
Barcelona、Catalonia、西班牙、08035
- Hospital Universitari Vall d Hebron
-
Barcelona、Catalonia、西班牙、08041
- Hospital de la Santa Creu i Sant Pau
-
L'Hospitalet de Llobregat、Catalonia、西班牙、08908
- Institut Catala d Oncologia Hospitalet Hospital Duran i Reynals
-
-
Navarre
-
Pamplona、Navarre、西班牙、31008
- Clinica Universidad de Navarra
-
-
Valencia
-
Valencia、Valencia、西班牙、46026
- Hospital Universitari i Politecnic La Fe
-
-
-
-
-
La Rioja、阿根廷、F5300COE
- Fundacion Centro Oncológico Riojano Integral para la Investigación y Prevención del Cáncer
-
-
Buenos Aires
-
CABA、Buenos Aires、阿根廷、C1280AEB
- Hospital Britanico de Buenos Aires
-
Capital Federal、Buenos Aires、阿根廷、C1426ANZ
- Instituto Alexander Fleming
-
-
Río Negro Province
-
Cipolletti、Río Negro Province、阿根廷、8324
- Fundacion Medica de Rio Negro y Neuquen
-
-
Tucumán Province
-
San Miguel de Tucumán、Tucumán Province、阿根廷、4000
- Exelsus Oncologia Clinica
-
-
-
-
-
Cheongju Chungbuk、韩国、28644
- Chungbuk National University Hospital
-
Goyang-si Gyeonggi-do、韩国、10408
- National Cancer Center
-
Seongnam-si, Gyeonggi-do、韩国、13620
- Seoul National University Bundang Hospital
-
Seoul、韩国、03080
- Seoul National University Hospital
-
Seoul、韩国、05505
- Asan Medical Center
-
Seoul、韩国、03722
- Severance Hospital Yonsei University Health System
-
Seoul、韩国、06351
- Samsung Medical Center
-
-
-
-
-
Kowloon、香港
- Princess Margaret Hospital
-
Shatin, New Territories、香港
- Prince of Wales Hospital, Chinese University of Hong Kong
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion:
- Participant has provided informed consent prior to initiation of any study specific activities/procedures.
- Age >= 18 years (or >= legal adult age within the country if it is older than 18 years).
- Completed 3-4 cycles of platinum-etoposide chemotherapy with concurrent durvalumab as first-line treatment of extensive-stage (ES)-SCLC prior to enrollment, without disease progression (ongoing response or stable disease) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1.
- Minimum life expectancy > 12 weeks.
- Toxicities attributed to prior anti-cancer therapy resolved to grade ≤ 1, unless otherwise specified, excluding alopecia or fatigue.
- Adequate organ function.
- Histologically or cytologically documented extensive-stage disease (American Joint Committee on Cancer, 2017, IV small-cell lung cancer (SCLC) [T any, N any, M1 a/b/c]), or T3 to T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan. Participants with prior limited-stage (LS)-SCLC are allowed if the interval is > 6 months since the end of previous therapy and progression, in discussion with the medical monitor.
Exclusion
- Symptomatic central nervous system (CNS) metastases, or leptomeningeal disease. Participants with treated brain metastases are eligible as per protocol.
- Prior history of severe or life-threatening events from any immune-mediated therapy.
- History of other malignancy within the past 2 years, with some exceptions as per protocol.
- Active or prior documented autoimmune or inflammatory disorders as per protocol.
- Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association > class II) within 6 months of first dose of study treatment.
- History of arterial thrombosis (e.g., stroke or transient ischemic attack) within 6 months of first dose of study treatment.
- Evidence of interstitial lung disease (ILD) or active, non-infectious pneumonitis.
- History of solid organ transplant.
- Major surgical procedures within 28 days of first dose of study treatment.
- Known human immunodeficiency virus (HIV) infection (participants with HIV infection on antiviral therapy and undetectable viral load are permitted with a requirement for regular monitoring for reactivation for the duration of treatment on study), hepatitis C infection (participants with hepatitis C that achieve a sustained virologic response after antiviral therapy are allowed), or hepatitis B infection (participants with hepatitis B surface antigen [HBsAg] or core antibody that achieve sustained virologic response with antiviral therapy are permitted with a requirement for regular monitoring for reactivation for the duration of treatment on the study).
- Receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 14 days prior to first dose of study treatment.
- History of allergic reactions or acute hypersensitivity reaction to antibody therapies, platinum chemotherapy, or etoposide.
- Participant with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment.
- Participant has known active infection requiring parenteral antibiotic treatment. Upon completion of parenteral antibiotics and resolution of symptoms, the participant may be considered eligible for the study from an infection standpoint.
- Treatment with live virus, including live-attenuated vaccination, within 4 weeks prior to the first dose of study treatment. Inactive vaccines (e.g., non-live or non-replicating agent) and live viral non-replicating vaccines (e.g., Jynneos for Monkeypox infection) within 30 days prior to first dose of study treatment.
- Prior therapy with any selective inhibitor of the delta-like ligand 3 (DLL3) pathway.
- Receiving another anti-cancer therapy. Adjuvant hormonal therapy for resected breast cancer is permitted.
- Treatment in an alternative investigational trial within 28 days prior to enrollment.
- Has received or is planning to receive consolidative chest radiation for extensive stage disease.
- Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment as per protocol.
- Female participants who are breastfeeding or who plan to breastfeed while on study as per protocol.
- Female participants planning to become pregnant or donate eggs while on study as per protocol.
- Female participants of childbearing potential with a positive pregnancy test assessed at screening by a highly sensitive serum pregnancy test.
- Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment as per protocol.
- Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment as per protocol.
- Male participants unwilling to abstain from donating sperm during treatment as per protocol.
- Participant has known sensitivity to any of the products or components to be administered during dosing.
- Participant has known sensitivity to any of the products or components to be administered during dosing.
- History or evidence of any other clinically significant disorder, condition or disease that, in the opinion of the investigator or physician if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
- Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, Clinical Outcome Assessments) to the best of the participant and investigator's knowledge. Participants who are unable to complete clinical outcome assessments are eligible.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Tarlatamab in Combination With Durvalumab
Participants will receive tarlatamab once every 2 weeks (Q2W) and durvalumab once every 4 weeks (Q4W). |
Intravenous (IV) infusion
其他名称:
IV infusion |
|
有源比较器:Durvalumab Alone
Participants will receive durvalumab Q4W alone. |
IV infusion |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
操作系统
大体时间:最长约3年
|
最长约3年
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
2 年操作系统
大体时间:2年
|
2年
|
|
无进展生存期 (PFS)
大体时间:最长约3年
|
最长约3年
|
|
总体反应(或)
大体时间:最长约3年
|
最长约3年
|
|
疾病控制 (DC) 率
大体时间:最长约3年
|
最长约3年
|
|
响应持续时间 (DoR)
大体时间:最长约3年
|
最长约3年
|
|
6 个月时的 PFS
大体时间:6个月
|
6个月
|
|
1 年无进展生存期
大体时间:1年
|
1年
|
|
2 年 PFS
大体时间:2年
|
2年
|
|
6 个月时的操作系统
大体时间:6个月
|
6个月
|
|
1 年操作系统
大体时间:1年
|
1年
|
|
3 年操作系统
大体时间:3年
|
3年
|
|
进展时间 (TTP)
大体时间:最长约3年
|
最长约3年
|
|
出现治疗中出现的不良事件 (TEAE) 的参与者人数
大体时间:最长约 9 个月
|
最长约 9 个月
|
|
根据不良事件通用术语标准 (CTCAE) 5.0 版,TEAE 达到 3 级或以上的参与者人数。
大体时间:最长约3年
|
最长约3年
|
|
患有严重 TEAE 的参与者数量
大体时间:最长约3年
|
最长约3年
|
|
因 TEAE 导致停止治疗的参与者人数
大体时间:最长约3年
|
最长约3年
|
|
发生致命 TEAE 的参与者人数
大体时间:最长约3年
|
最长约3年
|
|
出现治疗相关不良事件 (AE) 的参与者人数
大体时间:最长约 9 个月
|
最长约 9 个月
|
|
发生感兴趣的不良事件 (EOI) 的参与者数量
大体时间:最长约 9 个月
|
最长约 9 个月
|
|
Tarlatamab 的血清浓度
大体时间:第 1 天至约 6 个月
|
第 1 天至约 6 个月
|
|
形成抗tarlatamab抗体的参与者人数
大体时间:最长约 9 个月
|
最长约 9 个月
|
|
以欧洲癌症研究与治疗组织生活质量问卷30(EORTC-QLQ-C30)评估的身体功能首次恶化时间(TTD)
大体时间:基线至第13周和第25周
|
基线至第13周和第25周
|
|
使用EORTC-QLQ LC13量表测量的咳嗽疾病症状变化
大体时间:基线至第13周和第25周
|
基线至第13周和第25周
|
|
通过使用EORTC-QLQ LC13评估的胸痛疾病症状变化
大体时间:基线至第13周和第25周
|
基线至第13周和第25周
|
|
采用EORTC-QLQ LC13量表测量的呼吸困难疾病症状变化
大体时间:从基线到第13周和第25周
|
从基线到第13周和第25周
|
|
采用EORTC-QLQ-C30评估的总体健康状况的TTD
大体时间:基线至第13周和第25周
|
基线至第13周和第25周
|
|
以EORTC-QLQ-C30衡量的生活质量TTD
大体时间:从基线至第13周和第25周
|
从基线至第13周和第25周
|
合作者和调查者
赞助
调查人员
- 研究主任:MD、Amgen
出版物和有用的链接
一般刊物
- Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, Pogorzelski M, Hafliger S, Parkes A, Zhang Y, Hamidi A, Thompson CG, Wermke M. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. Lancet Oncol. 2025 Oct;26(10):1300-1311. doi: 10.1016/S1470-2045(25)00480-2. Epub 2025 Sep 8.
- Perol M, Yoshida T, Ahn MJ, Gay CM, Schuler M, Liu H, Sezer A, Bilici A, Korantzis I, Lim SM, Otsubo K, Juan-Vidal O, Chen Y, Schvartsman G, Wang H, Dingemans AC, Clarke JM, Desai A, Marigil M, Chen Y, Abidi B, Wang J, Sands J; DeLLphi-305 Investigators. Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2026 Oct 24. doi: 10.1056/NEJMoa2609482. Online ahead of print.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 20200041
- 2023-505989-29 (其他标识符:EU CT Number)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD 共享时间框架
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD 共享访问标准
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.